Udvalget for Humanmedicinske Lægemidler (CHMP) konkluderede, at fordelene ved Invega i en dosis på mellem 3 og 12 mg dagligt til behandling af skizofreni opvejer risiciene.
The Committee for Medicinal Products for Human Use (CHMP) decided that, at doses of between 3 and 12 mg a day, Invega’ s benefits are greater than its risks for the treatment of schizophrenia.